https://clinicaltrials.gov/study/NCT06055439?intr=cdh17&aggFilters=status:not&rank=2
This trial will be the catalyst for share price appreciation.
I'm keen for others thoughts on this one but it looks to me like they're planning on having the phase 2 primary completion wrapped up by mid 2026. That's a lot quicker than I anticipated and an enormous amount of confidence before they have dosed a single patient. Looking at the study overview, the estimated enrolment number of 135 patient's and the phases 1 and 2 listed would suggest as much?
Given the preclinic complete eradication of all cancer cells happened within a month, the preliminary data back end of the year is going to be of HUGE interest.
- Forums
- ASX - By Stock
- Ann: Clinical milestones for 2024 & 2023 successes highlighted
https://clinicaltrials.gov/study/NCT06055439?intr=cdh17&aggFilter...
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CHM (ASX) to my watchlist
(20min delay)
|
|||||
Last
1.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $12.67M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
CHM (ASX) Chart |
Day chart unavailable